Stroke four days after vaccination with a vector-based SARS-CoV-2 vaccine : Journal of Family Medicine and Primary Care

Secondary Logo

Journal Logo

Letter to Editor

Stroke four days after vaccination with a vector-based SARS-CoV-2 vaccine

Finsterer, Josef

Author Information
Journal of Family Medicine and Primary Care 11(11):p 7491-7492, November 2022. | DOI: 10.4103/jfmpc.jfmpc_814_21
  • Open

Since the introduction of both the vector-based and the messenger ribonucleic acid (mRNA)-based SARS-CoV-2 vaccines, adverse reactions have been occasionally reported, either in the medical literature or in public media.[1,2] One of these side effects is venous or arterial thrombosis due to suspected hypercoagulability.[3] Ischaemic stroke shortly after vaccination with a vector-based SARS-CoV-2 vaccine has been only rarely reported.

The patient is a 29-year-old, smoking, human immunodeficiency virus (HIV)-negative female, who was hospitalised at a primary care unit for acute onset vertigo and dysarthria a few hours after sexual intercourse. Cerebral imaging was not performed. She was discharged after improvement of symptoms within 1 day of observation. Vertigo completely resolved within the next 2 days. An outpatient neurologist recommended a cerebral magentic resonance imagign (MRI) which, 11 days after onset, showed a right cerebellar, subacute ischaemic lesion [Figure 1]. She did not carry any classical cardiovascular risk factors except for smoking but 4 days prior to the cerebrovascular event, she had undergone a first vaccination with a vector-based SARS-CoV-2 vaccine. Workup for other possible causes of cerebellar stroke revealed a positive bubble test, suggesting a patient foramen ovale (PFO), which was confirmed transesophageal echocardiography. The previous history was only positive for sepsis at 3 years of age. Clinical neurologic exam only revealed discrete ataxia on the left lower leg. Blood tests were non-informative. Serum interleukin-6 was 3.2 pg/mL (n, 0–7 pg/mL). The APC resistance was mildly increased. There was no indication for deep venous thrombosis. Cerebral MRI 19 days after the stroke confirmed the previously detected ischaemic lesion in the right cerebellar hemisphere with a tendency of regression in size. Time-of-flight-angiography did not show occlusion, stenosis, or atherosclerosis of intracerebral arteries. The patient was discharged symptom-free after 6 days with the recommendation to regularly take acetylsalicylic acid. She is currently scheduled for PFO closure with a device.

F1
Figure 1:
Cerebral MRI 11 days after the stroke showing a hyperintensity in the right cerebellar hemisphere on fluid attenuated inversion recovery (FLAIR) and diffusion weighted imaging (DWI), which was slightly hyperintense on apparent diffusion coefficient (ADC), and showed gadolinium enhancement being interpreted as subacute ischaemic lesion with a hyperintense, acute, reperfusion marker (HARM) phenomenon

The presented patient is interesting for juvenile, ischaemic stroke 4 days after vaccination with a vector-based SARS-CoV-2 vaccine in the presence of a PFO. An argument against a Valsalva manoeuvre during sexual intercourse and transmigration of thrombi from the right to the left cardiac chambers is that the patient previously had sexual intercourse several times without ever experiencing a cerebrovascular event. A further argument against paradoxical embolism is the absence of a deep venous thrombosis. Considering that a PFO was truly present, it is nonetheless conceivable that subclinical deep venous thrombosis had occurred and that these thrombi were asymptomatic in the leg but passed to the left atrium and resulted in the cerebellar stroke. An argument in favour of the PFO hypothesis is that venous thrombosis has been previously reported as a complication of vaccination with vector-based SARS-CoV-2 vaccines.[4] However, since there were no indications for deep venous thrombosis, paradoxical embolism was regarded as rather unlikely. Putative neurological side effects of SARS-CoV-2 vaccines so far reported include transverse myelitis, facial palsy, dizziness, headache, pain, muscle spasms, myalgia, and paresthesias.[5] More rarely reported were tremor, diplopia, tinnitus, dysphonia, seizures, and occasionally stroke, Guillain-Barré syndrome, and acute disseminated encephalomyelitis (ADEM).[5] However, establishing any causal link between vaccination and any of these neurologic abnormalities is challenging.[5]

In conclusion, this case shows that juvenile, ischaemic stroke may occur shortly after vaccination with a vector-based SARS-CoV-2 vaccine in a patient with the risk factors smoking and PFO. Whether stroke and vaccination were causally related or not remains speculative.

Declaration of patient consent

Informed consent was obtained.

Ethics committee approval

The study was approved by the institutional review board.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Mitchell OR, Dave R, Bekker J, Brennan PA Supraclavicular lymphadenopathy following COVID-19 vaccination:An increasing presentation to the two-week wait neck lump clinic?. Br J Oral Maxillofac Surg 2021; 59:384–5.
2. Klimek L, Chaker AM, Cuevas M Allergische Reaktionen auf COVID-19-impfungen –Was HNO-Ärzte wissen sollten –Teil 1:Allgemeine aspekte von allergien auf impfstoffe, immunologische grundlagen von allergien auf impfstoffe, immunmechanismen von allergischen und pseudoallergischen reaktionen;Teil 2:Charakteristiken der mRNA-impfstoffe BNT162b2 und mRNA-1273 zur prophylaxe von COVID-19, weitere Impfstoff-Kandidaten und assoziierte Immunphänomene;Teil 3:Praktische aspekte der prophylaxe, diagnostik und therapie von allergien auf COVID-19-Impfstoffe. Laryngorhinootologie 2021; 100:252–8.
3. Mekheal N, Roman S, Michael P Multiple arterial thrombosis in a COVID patient with no known comorbidities with mild elevation of D-Dimer. Cureus 2021; 13:e13207.
4. Carli G, Nichele I, Ruggeri M, Barra S, Tosetto A Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine. Intern Emerg Med 2021; 16:803–4.
5. Goss AL, Samudralwar RD, Das RR, Nath A ANA investigates:Neurological complications of COVID-19 vaccines. Ann Neurol 2021; 89:856–7.
Copyright: © 2022 Journal of Family Medicine and Primary Care